Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide
Author:
Publisher
Oxford University Press (OUP)
Subject
Pharmacology (medical),Rheumatology
Link
http://academic.oup.com/rheumatology/article-pdf/50/12/2270/17387196/ker270.pdf
Reference20 articles.
1. ASAS/EULAR recommendations for the management of ankylosing spondylitis;Zochling;Ann Rheum Dis,2006
2. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis;van der Heijde;Arthritis Rheum,2008
3. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis;Braun;Ann Rheum Dis,2003
4. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab;Baraliakos;Ann Rheum Dis,2005
5. Update on spondyloarthropathies;Khan;Ann Intern Med,2002
Cited by 24 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Differences and similarities between the EULAR/ASAS-EULAR and national recommendations for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe;The Lancet Regional Health - Europe;2023-10
2. POS0374 HOW WELL DO EULAR/ASAS-EULAR AND NATIONAL TREATMENT RECOMMENDATIONS FOR PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS ALIGN? IS IT TIME FOR AN UPDATE OF NATIONAL TREATMENT RECOMMENDATIONS?;Scientific Abstracts;2023-05-30
3. Disease Activity-Guided Stepwise Tapering but Not Discontinuation of Biologics Is a Feasible Therapeutic Strategy for Patients with Ankylosing Spondylitis: Real-World Evidence;Advances in Therapy;2022-02-02
4. Effectiveness of Subcutaneous Tumor Necrosis Factor Inhibitors in Patients With Ankylosing Spondylitis: A Real-World Prospective Observational Cohort Study in China;Frontiers in Pharmacology;2019-12-17
5. Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA);Annals of the Rheumatic Diseases;2019-01-23
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3